Association outlines UK legal position and current scientific research
BSAVA has released a new scientific document for the veterinary profession on the use of cannabidiol (CBD) in companion animals.
The document has been published in response to an increased interest in the use of CBD to treat cats and dogs. It was written by members of the BSAVA Scientific Committee, alongside specialists in internal medicine and neurology.
Included in the document are details on the legal position regarding the use of CBD oil in companion animals in the UK, as well as the pharmacokinetics and pharmacodynamics of CBD in humans and dogs and an overview of current scientific research.
Author and BSAVA Scientific Committee member, Caroline Kisielewicz, said: “Information regarding the effects of cannabinoids on animals is predominantly at the stage of pre-clinical testing of individual substances in mice, rats and guinea pigs. There are limited clinical studies looking at the effects of CBD in dogs, and no reported studies in cats.
“There are many reports describing possible beneficial effects and therapeutic potential in humans, and subsequently pet owners may ask their vet about using cannabinoids to treat veterinary patients. This document aims to provide a broad overview of the available evidence base and legal position in the UK for veterinary team members.”
The Use of cannabidiol (CBD) in dogs and cats information document is available for free on the BSAVA website.
Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.
